Time to onset of sustained ≥50% responder status in patients with focal (partial‐onset) seizures in three phase III studies of adjunctive brivaracetam treatment
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase III studies (NCT 00464269, NCT 00490035, and NCT 01261325). Patients were aged ≥16 years with well‐characterized focal (partial‐onset) seizures (FS) uncontrolled by 1–2 concomitant antiepileptic drugs. After an 8‐week baseline period, patients received study drug without up‐titration for a 12‐week (84‐day) treatment period. A patient was a sustained ≥50% responder on a particular day if they completed the entire treatment period through day 84 and was a ≥50% responder (based on percent reduction in FS frequency from baseline) both on that day and every successive day until day 84 (end of treatment period). In the pooled efficacy population (N = 1,160), 15.5%, 18.1%, and 19.4% of patients taking BRV 50, 100, or 200 mg/day, respectively, achieved SRS on day 1 versus 6.7% for placebo (p < 0.001). Statistically significant SRS was also achieved for most of the BRV‐treated groups in the three separate studies. This suggests that BRV has an early, sustained onset of action in a subset of responders. The incidence of adverse events during the first week was similar to that in the overall treatment period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169 · cited 9×
“and affinity for SV2A and rapid brain penetration in animal models.(1,2) We evaluated time to onset of SRS for adults with focal (partial-onset) seizures (FS) from three fixed-dose, randomized, double-blind, phase III studies of BRV (N01253/NCT00464269,(3) N01252/ NCT00490035,(4) and N01358/NCT01261325(5)).”
BackgroundMethodInfluential
Cited by
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“Time to onset of sustained ≥50% responder status was assessed for patients receiving placebo or BRV 50 mg/day, 100 mg/day, or 200 mg/day (n=1,160).(99) Sustained responders were defined as patients who completed the entire treatment period, and were ≥50% responders from the first day of 50% reduction in seizure freque…”
MethodSelf-citationKlein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
“A post hoc analysis of the pooled phase III trials assessed the time to onset of sustained ≥ 50% responder status in patients randomized to BRV 50–200 mg/day or PBO [34].”
BackgroundMethodSelf-citationA brief review on efficacy and safety of brivaracetam in the management of partial onset epilepsy
Vithoba Panchal, G., & Nath Mishra, V. (2021) · IP Indian Journal of Neurosciences · doi:10.18231/j.ijn.2021.017 · Cited by 2
Metadata
- Authors
- Klein, P., Johnson, M. E., Schiemann, J., & Whitesides, J.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2016-12-18
- Volume
- 58
- Issue
- 2
- Pages
- e21-e25
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2564886542
- Cited by
- 37
- References
- 1
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Time to onset of sustained ≥50% responder status in patients with focal (partial‐onset) seizures in three phase III studies of adjunctive brivaracetam treatment. https://app.cochat.ai/papers/10.1111/epi.13631
- The paper
- Klein, P., Johnson, M. E., Schiemann, J., & Whitesides, J. (2017). Time to onset of sustained ≥50% responder status in patients with focal (partial‐onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. https://doi.org/10.1111/epi.13631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.